News & Updates
Filter by Specialty:
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
The use of metformin, fluvoxamine, or ivermectin in an outpatient setting did not appear to prevent progression to severe COVID-19, according to results of the phase III COVID-OUT trial.
Metformin, ivermectin, fluvoxamine OUT for severe COVID-19 prevention?
11 Oct 2022
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
Bronchodilators, used in the treatment of chronic obstructive pulmonary disease (COPD), did not appear to benefit individuals with a history of smoking and respiratory symptoms who did not have airflow obstruction, results of the US-based RETHINC* study showed.
Bronchodilators ineffective in symptomatic, tobacco-exposed patients without COPD
08 Oct 2022
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
